Company intelligence / Profile preview

Galera Therapeutics, Inc.

Malvern, Pennsylvania, USAgaleratx.com ↗

Ownership: Public · GRTX
Employees: ~3
Development stage: Phase 2

Overview

Galera’s lead candidate avasopasem manganese completed a Phase III trial for severe oral mucositis in head and neck cancer but did not meet its primary endpoint for statistical significance despite showing some reduction trends. Rucosopasem manganese showed safety and early efficacy signals in NSCLC with ongoing Phase II work at the time of company wind-down. The company also had early-stage programs targeting breast cancers using NOS inhibitors.

Therapeutic areas: OncologyNephrology
Modalities: Small molecules (specifically superoxide dismutase mimetics)
Industry: Biotech

Drug pipeline

5 assets

avasopasem manganese

4 more assets in the full pipeline.

Request access →

Financials

Market cap: $3.6B
Total revenue: $0
Enterprise value: $3.6B

Beyond the preview

Go deeper on Galera Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Galera Therapeutics, Inc..

Explore the full profile